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Background: LAM is a rare disease of women categorised by lung cysts and lymphatic abnormalities. The disease
occurs sporadically or associated with Tuberous Sclerosis Complex (TSC-LAM). Angiomyolipoma, a benign tumour, prone
to haemorrhage, occurs mostly in the kidneys in many of these patients. Treatment guidelines exist for angiomyolipoma
in patients with TSC but the natural history of angiomyolipoma in sporadic LAM has not been studied.
Aims: To document the natural history of angiomyolipoma in a national cohort of patients with sporadic LAM to inform
tumour screening and surveillance protocols.
Methods: Demographic data, clinical features, lung function and tumour size were obtained from clinical records of
patients attending the National Centre for LAM in Nottingham, UK.
Results: 122 patients with definite or probable LAM by European Respiratory Society criteria were identified. One
hundred and seven had sporadic LAM, of which 53 (50%) had at least one angiomyolipoma. In patients with sporadic
LAM presentation of angiomyolipoma preceded or followed onset of lung symptoms by up to 11 and 38 years
respectively. Mean tumour size was 28 mm (range 5-140 mm) at presentation and growth was 1.8 mm/yr (95% C.I.
0.42-3.82) thereafter. Eleven patients with sporadic LAM had had a nephrectomy due to angiomyolipoma bleeding.
The need for intervention did not differ between those with TSC-LAM and sporadic LAM.
Conclusions: Patients with LAM have a high prevalence of symptomatic angiomyolipoma which can present at any
time. Angiomyolipoma in sporadic-LAM have a similar risk of bleeding to those with TSC. All patients should be
screened for angiomyolipoma at diagnosis of lung disease by MRI scanning and the tumours require continuous
monitoring.
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Lymphangioleiomyomatosis (LAM) is a rare systemic dis-
ease, almost exclusively affecting women with a prevalence
of 5–10/million women [1]. LAM causes lung cysts and
lymphatic abnormalities leading to recurrent pneumo-
thorax, respiratory impairment and chylous collections
[2]. LAM occurs both sporadically and in patients with
tuberous sclerosis complex (TSC). Angiomyolipoma, a* Correspondence: simon.johnson@nottingham.ac.uk
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unless otherwise stated.benign tumour, is present in up to half of patients with
sporadic LAM [3,4] and nearly all patients with TSC-
LAM [5,6].
The majority of angiomyolipomas do not cause symp-
toms although larger tumours are at risk of bleeding.
Failure to identify and prophylactically treat larger tu-
mours with either selective embolisation or nephron
sparing surgery can result in retroperitoneal haemor-
rhage and sometimes a nephrectomy [7]. More recently,
pharmacologic inhibition of the kinase mTOR has been
shown to reduce angiomyolipoma volume in patients
with TSC and sporadic LAM [8-10] and mTOR inhibi-
tors are now recommended for treatment of angiomyoli-
poma in TSC [11].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Figure 1 Imaging appearances of angiomyolipomas. (a)
Characteristic CT appearance of large right renal angiomyolipoma
showing a heterogenous lesion with areas of fat density and a small
lesion in the contralateral kidney. (b) Tiny exophytic cortical
angiomyolipoma in the right kidney assigned a measurement of
5 mm (arrow). (c) & (d) CT and ultrasound appearances respectively
of the same 40 mm angiomyolipoma.
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based on case series [12,13] and suggest that angiomyoli-
poma in patients with TSC grow more rapidly and are
more prone to complications than angiomyolipoma in
non-TSC patients [7]. However data on the natural his-
tory of angiomyolipoma in sporadic LAM are very
sparse and it is not clear if angiomyolipoma in these pa-
tients really are less prone to haemorrhage and should
be treated differently from those with TSC. We have
examined the clinical characteristics, growth rate and com-
plications of angiomyolipoma in women with sporadic-
LAM to optimise screening protocols for these patients.
Methods
Patients
Patients were recruited from the National Centre for
LAM in Nottingham UK, a referral centre providing
comprehensive care for both sporadic and TSC-LAM.
All patients were over the age of 18 years and had either
definite or probable LAM according to European Re-
spiratory Society (ERS) criteria [14]; those with possible
LAM were excluded. TSC was diagnosed according to
current criteria [15]. All patients had a clinical examin-
ation looking for signs of TSC including a dermatologic
examination with a Woods light. In keeping with the
ERS LAM guidelines; where TSC could not be excluded
clinically, patients were evaluated by a clinical geneticist.
Ethical approval was obtained from the Trent Multi-
Centre Research Ethics Committee (NRES 07/H0403/
165 and NRES 05/Q2403/187) and all patients provided
informed consent. Patient histories were taken in a stan-
dardised format for clinical purposes and baseline as-
sessment included screening for TSC as recommended
in the ERS LAM guidelines [14]. Lung function tests
were measured according to ERS/British Thoracic Soci-
ety standards as part of clinical care [16]. Lymphatic in-
volvement was evaluated at baseline and defined as the
presence of chylous collections in the abdomen or
thorax, abdominal or pelvic lymphadenopathy, diffuse
lymphatic enlargement or lymyphangioleiomyomas vis-
ible by CT scanning. Renal history and imaging was ob-
tained from both the referring centre and investigations
performed at the National LAM Centre. Angiomyoli-
poma imaging was performed for routine clinical care
according to the LAM Centre angiomyolipoma protocol
where patients have cross sectional imaging of their
renal tract, at or as soon after diagnosis as practical,
and for those with angiomyolipoma, a measurement of
tumour size at yearly intervals thereafter. Tumour size
measurements obtained prior to attending the LAM
Centre were performed at the referring clinician’s dis-
cretion. Tumour size was expressed as the longest diameter
of angiomyolipomas measured by either ultra-sound (US),
computerised tomography (CT) or magnetic resonanceimaging (MRI) as previously described (Figure 1) [9].
Measurements were performed by either the reporting
radiologist, or a member of the study team (SJ). Unquanti-
fiable small tumours were assigned a measurement of
5 mm. Tumour measurements post angiomyolipoma sur-
gery, post embolization or when using mTOR inhibitors
were excluded from the analysis of tumour growth.
Analysis
Groups were compared using linear regression, chi
square or t-tests. Tumour growth rate (mm/yr) was de-
fined as the slope of a regression line fitted to tumour
measurements for patients who had repeated imaging.
Tumour size categories were compared by a 1 way ana-
lysis of variance (ANOVA). Time to intervention was
analysed by Kaplan-Meier analysis. Intervention was de-
fined as a composite endpoint comprising action taken
in response to spontaneous tumour bleeding, use of an
mTOR inhibitor for angiomyolipoma, or referral to an
interventional service at the discretion of the supervising
clinician. Calculations were performed using Graphpad
Prism version 6.00, (GraphPad Software, San Diego
California USA) and Stata v11 (Texas)).
Results
Patient cohort
One hundred and twenty two patients with definite or
probable LAM by ERS criteria were identified [14]. One
hundred and seven patients had sporadic LAM and 15
TSC-LAM. Of those with sporadic LAM, the mean age
at diagnosis with respiratory disease was 35.3 years (SD
10.4). The mean age at the time of the study was 50 years
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Figure 2 Angiomyolipoma may present at any point in the
disease course. Frequency distribution of angiomyolipoma
presentation relative to presentation with respiratory disease
(respiratory diagnosis is at 0 years). Detection of angiomyolipoma
may have been due to symptomatic disease or screening.
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to shortness of breath in 53%, pneumothorax in 28%,
cough in 4%, and haemoptysis in 3%. The remaining
12% presented with either extra-pulmonary manifesta-
tions or were found to have LAM after investigation
for unrelated problems.
Presentation with angiomyolipoma
Of the 107 patients with sporadic LAM, 53 (50%) had,
or had had, at least one renal angiomyolipoma. Two pa-
tients with renal angiomyolipoma had co-existent hep-
atic angiomyolipomas. Hepatic angiomyolipomas were
not included in the analysis. The mean age at discovery
of angiomyolipoma was 39.1 years (SD 13.2). Nineteen
out of 53 (36%) of those with angiomyolipoma presented
due to symptoms. In 11 patients this was abdominal or
flank pain, in three haematuria, in three palpable mass
and in two abdominal bloating. Of these patients present-
ing with angiomyolipoma symptoms, 11 were treated by
nephrectomy, including one with renal bleeding during
pregnancy. The median age at nephrectomy was 23 (range
13–49). Nine of these 11 had bilateral angiomyolipoma.
The remaining 64% of angiomyolipomas were detected by
screening after the diagnosis of lung disease (Table 1).
In 10 patients detection of angiomyolipoma preceded
the diagnosis of lung disease by up to 11 years. In 10,
the diagnosis of lung disease was made at the time of
renal presentation but in the remainder, angiomyoli-
poma was detected up to 38 years after the onset of respira-
tory symptoms (Figure 2). Reliable tumour measurements
for patients treated with nephrectomy at diagnosis were not




Present Absent p value
Number of patients 53 54 15
Mean age at respiratory
presentation* (years)
32.3 37 0.18 31.8
Mean disease duration*
(years)
14.4 15.2 0.21 10.5
Ever had pneumothorax# (%) 16 (32) 13 (24) 0.37 40
Lymphatic disease
detected# (%)
6 (11) 10 (19) 0.036 13








57.7 59.3 0.79 47
p = angiomyolipoma present vs. absent for patients with sporadic LAM.
Angiomyolipoma was present in all patients with TSC-LAM.
*p value from t test.
#p value from chi squared test.data. At presentation, the mean tumour size for patients
with sporadic LAM was 28 mm (SD 12.6, Table 2). The
presence of angiomyolipoma was not associated with
duration of disease (p = 0.72) or the degree of loss of
FEV1 (p = 0.37). Patients with angiomyolipoma were
less likely to have lymphatic involvement than those
without angiomyolipoma (p = 0.036) but other clinical
features did not differ significantly between groups
(Table 1).
Angiomyolipoma were present in all patients with
TSC-LAM and significantly more common than in those
with sporadic-LAM (p < 0.0001, Table 2). Compared with
TSC-LAM, patients with sporadic LAM tended to have
smaller tumours which were less often bilateral. How-
ever there was no significant difference in the incidenceTable 2 Comparison of angiomyolipoma characteristics in
patients with sporadic and TSC-LAM
Sporadic-LAM TSC-LAM p value




Mean age at renal
presentation* (years)
39 38 NS
Mean tumour size at
presentation* (mm)
29 61 0.006




Nephrectomy# (%†) 21 13 NS
*p value from t test. NS = not significant.
#p value from chi squared test.
†percentage of those with angiomyolipoma.
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groups (Table 2).
Natural history of angiomyolipoma
More than one tumour measurement was available for
31 tumours from 26 patients with sporadic LAM. The
mean duration of follow up was 3.8 years (SD 2.25).
Seventeen (55%) tumours increased in size, nine (29%)
did not change and five (16%) appeared to reduce in size
(Figure 3a). The mean rate of growth for angiomyoli-
poma in sporadic LAM was 1.8 mm/year (95% confi-
dence interval 0.42-3.82). Although there was no overall
relationship between tumour size and growth, there was
a trend toward larger tumours growing more rapidly
(Figure 3b) and only those 30 mm or larger grew by






















































Figure 3 Angiomyolipoma growth and tumour size. (a) Serial tumour m
more than one measurement was available in patients with untreated ang
growth. (c) Angiomyolipoma for patients with sporadic LAM categorised a
and range for tumour growth by size category. There is no difference in m
but growth of >10 mm/year was only observed in tumours greater than 30The median time from identification of angiomyolipoma
to a clinically significant renal event, defined as referral for
embolization or surgery, mTOR inhibitor treatment,
bleeding or other tumour symptom, was 34 years for
patients with sporadic LAM and 25 years for TSC-
LAM (range 0–43) (Figure 4). There was no significant
difference in clinically significant renal events between
those with sporadic or TSC-LAM.
Discussion
To our knowledge this is the first study to examine the
natural history of angiomyolipoma in a large cohort of
patients with sporadic LAM. Our aim was to understand
the growth and incidence of bleeding in patients with
sporadic LAM to develop better screening protocols for
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Figure 4 Time to need for intervention for angiomyolipoma.
Kaplan-Meier curves show the time to a significant renal event
(categorised as spontaneous tumour bleeding, use of an mTOR inhibitor,
or referral to an interventional service at the discretion of the supervising
clinician) for patients with sporadic and TSC-LAM. There was no
significant difference in the need for intervention between patients
with sporadic and TSC-LAM.
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present at any time during the clinical course and are
prone to growth and haemorrhage. Tumour presence
cannot be predicted by the extent of the lung disease or
other clinical features. This is important, as although pa-
tients with LAM are generally under regular follow up for
lung disease, renal angiomyolipomas may be neglected
and present with bleeding resulting in loss of renal func-
tion even in those with mild lung disease.
Previous series of angiomyolipoma may have underes-
timated the rates of TSC and LAM, particularly those
with milder clinical features [17]. For this reason it has
not been possible to address whether patients with non-
TSC related angiomyolipoma are truly at lower risk of
complications and should be treated differently from
those with TSC. In contrast to previous studies, our
findings suggest that patients with sporadic LAM and
angiomyolipoma have a similar risk of complications to
both historical series of those with TSC [7,18,19] and
with the small number of TSC-LAM patients within our
cohort.
Eleven of 53 patients had a nephrectomy due to haem-
orrhage from an angiomyolipoma. Nephrectomy due to
bleeding generally preceded the diagnosis of lung disease
and the histological type of renal tumour was unknown
at presentation. These patients had a mean age at neph-
rectomy of 23 years whereas the mean age at renal pres-
entation of the cohort as a whole was 39 years and it is
likely that these patients had more aggressive and rapidly
growing tumours.Despite this being one of the largest studies of the be-
haviour of angiomyolipoma, and the first to document
growth over time, our findings need to be interpreted
with some caution as some of these data are retro-
spective and some patients had had treatment for
symptomatic tumours prior to enrolment. As these
treated tumours were probably larger and more aggressive,
overall growth rates and the incidence of complications
may be underestimated. Furthermore, some outcome data
are based upon surrogate endpoints such as referral for an
intervention, which may have been influenced by factors
other than tumour size alone. In the cohort studied, more
patients with sporadic LAM were referred electively for
consideration of an intervention than those with TSC.
Additionally, data were collected using different imaging
modalities and protocols which may impact upon the
growth data, particularly where smaller lesions may be of
similar size to the slice intervals used in cross sectional im-
aging. Further, as ultrasound is not as accurate for size
measurements as CT or MRI and also less reliable at iden-
tifying the fat poor components of angiomyolipomas we at-
tributed a value of 5 mm to all tumours with a longest
diameter of 5 mm or less, and these issues may explain
why some of the tumours appeared to shrink over time.
The study also examines only tumour size and does
not account for the presence of vascular aneurysms
which are also associated with bleeding [18]. Analysing
the vascular anatomy of these tumours may be required
to improve stratification of bleeding risk and can be
done with both contrast CT and MRI.
Implications for clinical practice
Guidelines for patients with TSC have been recently
published which recommend MRI of the abdomen to as-
sess the progression of angiomyolipoma (and renal cystic
disease) every 1–3 years throughout the lifetime of the
patient. Intervention is recommended for tumours larger
than three cm which is a more aggressive approach than
that previously taken [11]. Patients with sporadic LAM
are less prone to loss of renal function than those with
TSC who commonly have multiple angiomyolipomas
and may also have polycystic kidney disease. However,
our findings suggest that patients with sporadic LAM
are at significant risk of bleeding from angiomyolipoma,
that these tumours may present at any point in the dis-
ease course, and grow unpredictably at a rate independ-
ent of progression of the lung disease. Although, from
somewhat limited data, our findings suggest that only
tumours greater than 30 mm are likely to grow in excess
of 10 mm/yr and reach a size of 40–45 mm before fur-
ther imaging and thus be at greater risk of haemor-
rhage. We would therefore suggest that all patients are
screened for the presence of angiomyolipoma at diag-
nosis by MRI. For those with tumours less than
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for tumours between 11 and 30 mm in diameter, at 12
monthly intervals. For tumours greater than 30 mm,
repeat imaging should be performed at 6 monthly in-
tervals or referred for consideration of an intervention
at that point. All patients with angiomyolipoma should
be warned of the symptoms of bleeding and imaging
should be performed urgently in the presence of new
symptoms possibly attributable to angiomyolipoma.
In summary, patients with sporadic LAM have a high
prevalence of symptomatic angiomyolipoma which can
present at any time during the course of the disease.
Angiomyolipoma in sporadic LAM have a similar risk of
bleeding to those with TSC and require continuous moni-
toring. Prospective evaluation of large cohorts of patients
with LAM in the developing specialist services is required
to improve understanding of the natural history, optimal
screening protocols and risk stratification of these tumours.
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